CAH
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/E and PEG (1.29) suggest fair valuation relative to growth, though Graham Number is unavailable.
- Trading near intrinsic value
- Attractive Forward P/E of 17.25
- Very low Price/Sales
- Trailing P/E is relatively high at 28.76
Growth rates are robust and outperforming many sector peers.
- 19.4% Earnings growth
- 18.8% Revenue growth
- Strong analyst target price of $248.27
- Recent Q/Q EPS growth decline of -22.7%
Long-term price performance and earnings reliability are excellent.
- 5-year price change of +270.8%
- Consistent history of earnings surprises
Health is the primary weakness; liquidity ratios suggest potential stress.
- Piotroski F-Score of 4/9 indicates stability
- Current Ratio < 1.0
- Quick Ratio of 0.38 is critically low
- Negative Price/Book ratio
Dividend is safe but not a primary driver for total return.
- Low payout ratio (29.32%) ensures safety
- Low dividend yield of 1.02%
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for CAH and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
CAH
Cardinal Health, Inc.
Primary
|
+270.8% | +159.6% | +48.8% | +24.1% | -5.2% | -6.6% |
|
EW
Edwards Lifesciences Corporation
Peer
|
+5.0% | +13.6% | +30.4% | +10.6% | +18.3% | +3.5% |
|
ARGX
argenx SE
Peer
|
+120.6% | +95.7% | +20.5% | -7.4% | -16.1% | -2.4% |
|
ALNY
Alnylam Pharmaceuticals, Inc.
Peer
|
+114.5% | +67.5% | +29.6% | -32.7% | -2.8% | -2.3% |
|
ZTS
Zoetis Inc.
Peer
|
-23.5% | -16.7% | -29.9% | -25.4% | -14.7% | +0.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
CAH
Cardinal Health, Inc.
|
NEUTRAL | $47.03B | 28.76 | -% | 0.7% | $199.85 | |
|
EW
Edwards Lifesciences Corporation
|
NEUTRAL | $50.08B | 37.85 | 13.5% | 23.2% | $86.3 | Compare |
|
ARGX
argenx SE
|
BULLISH | $43.35B | 35.74 | 20.2% | 30.4% | $700.45 | Compare |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
BEARISH | $41.57B | 135.09 | 73.3% | 8.4% | $313.41 | Compare |
|
ZTS
Zoetis Inc.
|
BULLISH | $53.39B | 20.34 | 49.9% | 28.2% | $120.82 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-15 | HALL PATRICIA HEMINGWAY | Director | Stock Award | 381 | $79,183 |
| 2026-02-27 | GREENE MICHELLE D | Chief Technology Officer | Sale | 2,746 | $627,387 |
| 2026-02-18 | ALT AARON E. | Chief Financial Officer | Sale | 2,328 | $524,964 |
| 2026-02-06 | HALL PATRICIA HEMINGWAY | Director | Sale | 4,000 | $918,880 |
| 2026-01-15 | PITTEROFF VALERIE CHRISTINE | Officer | Stock Award | 3,982 | $849,201 |
| 2025-11-05 | KENNY GREGORY B | Director | Stock Award | 1,702 | - |
| 2025-11-05 | MUSSLEWHITE ROBERT W | Director | Stock Award | 1,067 | - |
| 2025-11-05 | BRENNAN MICHELLE | Director | Stock Award | 1,067 | - |
| 2025-11-05 | RAMAKRISHNA SUDHAKAR | Director | Stock Award | 1,067 | - |
| 2025-11-05 | JOHRI AKHIL | Director | Stock Award | 1,067 | - |
| 2025-11-05 | HALL PATRICIA HEMINGWAY | Director | Stock Award | 1,067 | - |
| 2025-11-05 | KILLEFER NANCY | Director | Stock Award | 1,067 | - |
| 2025-11-05 | AZELBY ROBERT W | Director | Stock Award | 1,067 | - |
| 2025-11-05 | MUNDKUR CHRISTINE A | Director | Stock Award | 1,067 | - |
| 2025-11-05 | EVANS DAVID C | Director | Stock Award | 1,067 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Cardinal Health filed its Form 10-Q for the first quarter of fiscal 2026 on October 30, 2025. The filing includes disclosures regarding risk factors and unregistered sales of equity securities, although specific financial performance metrics were not provided in the available excerpts.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning CAH from our newsroom.